NCT05265273 2026-03-13
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 2/3 Recruiting
Clinical Trials
6 trialsNCT06055959 2026-02-27
ziMyG
UCB Pharma
Phase 2/3 Recruiting
NCT06149559 2026-02-27
roMyG
UCB Pharma
Phase 2/3 Recruiting
NCT04833894 2026-02-18
ADAPT Jr
argenx
Phase 2/3 Recruiting
NCT05374590 2026-02-02
ADAPT Jr +
argenx
Phase 2/3 Enrolling by invitation
NCT06193889 2026-01-30
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting